

Join Us
For A Free
Virtual Forum



VIRTUAL FORUM



Evolving Pharmacology Of Depression: Beyond The Monoamine Hypothesis

Tuesday, October 9, 2018 | 12pm ET | 9am PT

According to the World Health Organization, major depressive disorder (MDD) currently impacts 300 million individuals worldwide and is the leading cause of disability globally. Current treatment strategies for depression are effective in one-third to half of those seeking treatment, leaving a large unmet need for new therapeutic options. Since the 1960's, traditional pharmacological treatment strategies have centered on modulating serotonin, dopamine, and/or norepinephrine neurotransmitters systems. However, within the last few decades, research has begun to explore other neurotransmitter systems like GABA, glutamate, and opioid neuropeptide, as well as targets within the neuroendocrine, genetic, and inflammatory signaling systems that are moving psychiatry beyond the monoamine hypothesis.

In this Virtual Forum you will hear from Richard Jackson, MD, and Robin Nelson, MD, as they discuss some of the critical issues facing depression pathophysiology and treatment in current behavioral health care settings, focused on strategies moving beyond the traditional monoamine neurotransmitter targets and modalities with novel mechanisms of action that are on the horizon for depression treatment.

Speakers are paid consultants to Otsuka Pharmaceutical Development & Commercialization, Inc.

Robin Nelson, MD

Psychiatrist, DGR Behavioral Health LLC & Caron Treatment Centers



Richard Jackson, MD

Founder, The Neurobehavioral Medicine Group; Senior Psychiatrist, Women's Huron Valley Correctional Facility; Associate Clinical Professor, Department of Psychiatry, School of Medicine, Wayne State University; Assistant Clinical Adjunct Professor, Department of Psychiatry, School of Medicine, University of Michigan



Rachel Self, PhD, Senior Medical Science Liaison, will be the moderator of this event.

Visit **www.PsychU.org/events/virtual-forums**
to learn more and register today.



Tune In To PsychU Radio: www.PsychU.org/radio



Follow Us On Twitter: [@PsychUCommunity](https://twitter.com/PsychUCommunity)

PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU's contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
Copyright © 2018 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD

December 2017 MRC2.CORP.X.02248